^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    AC0176

    i
    Other names: AC0176, AC-0176, AC 0176, AC176
    Company:
    Accutar Biotech
    Drug class:
    Androgen receptor degrader
    Related drugs:
    2ms
    A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov)
    P1, N=28, Terminated, Accutar Biotechnology Inc | Trial completion date: Nov 2024 --> Mar 2024 | Active, not recruiting --> Terminated; Subject benefit-risk ratio changes, sponsor decides to voluntarily terminate study
    Trial completion date • Trial termination • Metastases
    |
    AC0176
    4ms
    A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov)
    P1, N=8, Terminated, Accutar Biotechnology Inc | Trial completion date: Jan 2026 --> Oct 2023 | Active, not recruiting --> Terminated | Trial primary completion date: Jan 2025 --> Oct 2023; Subject benefit-risk ratio changes, sponsor decides to voluntarily terminate study
    Trial completion date • Trial termination • Trial primary completion date • Metastases
    |
    AC0176
    7ms
    A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov)
    P1, N=8, Active, not recruiting, Accutar Biotechnology Inc | Recruiting --> Active, not recruiting | N=150 --> 8
    Enrollment closed • Enrollment change • Metastases
    |
    AC0176
    7ms
    A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov)
    P1, N=36, Active, not recruiting, Accutar Biotechnology Inc | Recruiting --> Active, not recruiting | Trial completion date: Mar 2024 --> Nov 2024 | Trial primary completion date: Mar 2023 --> Apr 2024
    Enrollment closed • Trial completion date • Trial primary completion date • Metastases
    |
    AC0176